Form 4: Dianthus Therapeutics Director Jonathan Violin Reports Stock Option Grant

Director Jonathan Violin reports the acquisition of stock options in Dianthus Therapeutics.

Summary

• On May 23, 2024, Jonathan Violin, a director of Dianthus Therapeutics, Inc., was granted stock options to purchase 11,000 shares of common stock.
• The exercise price of the options is $21.77 per share.
• The options vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2025 Annual Meeting of Stockholders, subject to continued service.
• The options expire on May 22, 2034.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing regarding stock option grants, which is generally neutral. The grant itself can be seen as a positive sign of aligning director interests with shareholders, but it's not a major event.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service to the company.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
• The size of the grant (11,000 shares) would need to be compared to similar grants at peer companies to assess its relative value.
• Companies like Amgen, Gilead, and Biogen also use stock options as part of their compensation strategy.

Stakeholder Impact

• The stock option grant could have a minor positive impact on shareholder sentiment by aligning director interests with those of shareholders.

Key Dates